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ABSTRACT
Introduction: stem cells may origi-
nate and perpetuate the tumor growth, 
but they are poorly known in glioma-
genesis. Metallothioneins (MTs) are 
proteins involved in oncogenesis and 
immunopositivity, for MT may be 
used as a stem cell mutation marker. 
Objective: to study the MT expres-
sion in the ENU experimental mo-
del and to establish an experimental 
model to track glioma stem cells in 
early oncogenesis. Methods: Thirty-
six male Wistar rats were divided 
into two groups; the experimental 
group was treated within 24 hours 
after birth (neonate rats) with a sin-
gle dose of subcutaneously injected 
N-ethyl N-nitrosourea ENU (40 mg/
kg body weight). The control animals 
were injected with the same volume 
of saline. These experimental animals 
were subdivided into three groups 
according to the euthanize time, as 
follows: the Group 1 (G1) was eutha-
nized at the age of 30 days; the Group 
RESUMO
Introdução: células-tronco podem 
originar e perpetuar o crescimento 
tumoral, porém são pouco conhecidas 
na gliomagênese. As metalotioneínas 
(MTs) são proteínas envolvidas na 
oncogênese, e sua a imunopositividade 
pode ser utilizada como marcador de 
mutação de células-tronco. Objetivo: 
estudar a expressão de MT no modelo 
experimental da ENU e estabelecer um 
modelo experimental para monitorar as 
células-tronco glioma na oncogênese. 
Métodos: Trinta e seis ratos machos 
da raça Wistar foram divididos em dois 
grupos; o grupo de animais experimental 
foi tratado dentro de 24 horas após o 
nascimento (ratos neonatos) com uma 
dose única de N-etil N-nitrosoureia 
(ENU) (40 mg/kg). Nos animais do 
grupo controle, injetou-se o mesmo 
volume de solução salina. Os animais do 
grupo experimental foram subdivididos 
em três grupos de acordo com o tempo 
da eutanásia, como se segue: o Grupo 
1 (G1) sofreu eutanásia com a idade de 
RESUMEN
Introducción: células madre pueden 
originar y perpetuar el crecimiento tu-
moral, sin embargo son poco conocidas 
en la gliomagénesis. Las metalotioneí-
nas (MTs) son proteínas involucradas en 
la oncogénesis, y la inmunopositividad 
de las MTs puede ser utilizada como 
marcador de mutación de las células 
madres. Objetivo: estudio de la expre-
sión de MT en el modelo experimental 
de la N-etil N-nitrosoureia (ENU) y es-
tablecer un modelo experimental para el 
seguimiento de las células madre en la 
oncogénesis glioma. Métodos: treinta y 
seis ratas machos Wistar fueron dividi-
das en dos grupos, un grupo de animales 
experimentales fue tratado dentro de 24 
horas después del nacimiento (ratas neo-
natas) con una dosis única de ENU (40 
mg/kg). Los animales del Grupo Control 
fueron inyectados con el mismo volu-
men de solución salina. Los animales 
del Grupo Experimental fueron subdivi-
didos en tres grupos de acuerdo con el 
tiempo de eutanasia, así como sigue: el 
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2 (G2), at the age of 180 days and the 
Group 3 (G3) was euthanized soon 
after the appearing of signs of the 
existence of nervous system tumors, 
at an average age of 321 days. Im-
munohistochemical detection of MT 
protein in cold acetone-fixed paraffin 
embedded spine cord sections was 
performed by the streptavidin-avidin-
biotin-immuno peroxidase complex 
method. Results: by using the expe-
rimental model of gliomagenesis in-
duced by the N-ethyl N-nitrosourea, it 
was possible to detect putative tumor 
stem cells in early oncogenesis, to 
analyze a field cancerization process 
and to observe a close morphologi-
cal relationship between MT positive 
cells and blood vessels. Conclusions: 
this reproducible experimental model 
allows further studies on the origins, 
development and regulating factors 
involved in gliomagenesis.
KEYWORDS: Glioma; 
Metallothionein; Stem cells
30 dias; o Grupo 2 (G2), com 180 dias 
e o Grupo 3 (G3) sofreu eutanásia logo 
após o surgimento de sinais de existência 
de tumor do sistema nervoso, com uma 
média de idade de 321 dias. A detecção 
imunohistoquímica da proteína MT em 
cortes da medula espinhal fixadas em 
acetona fria e embebidas em parafina 
foi realizada pelo método do complexo 
streptavidina-avidina-biotina-imuno 
peroxidase. Resultados: por meio de 
modelos experimentais de gliomagenese 
induzida pela N-etil N-nitrosoureia, 
foi possível detectar células-tronco de 
tumor putativo no início da oncogênese, 
analisar um processo de cancerização 
de campo e observar uma relação 
morfológica entre células positivas para 
MT e vasos sanguíneos. Conclusões: 
este modelo experimental reprodutível 
permite outros estudos sobre a origem, 
desenvolvimento e fatores reguladores 
da gliomatogênese.
DESCRITORES: Glioma; 
Metalotioneína; Células-tronco
Grupo G1 sufrió eutanasia con la edad 
de 30 días; el Grupo G2, con 180 días y 
el Grupo G3, después del surgimiento de 
señales de existencia de tumor del siste-
ma nervioso, con un promedio de edad 
de 321 días. La detección inmunohisto-
química de la proteína MT en cortes de 
médula espinal fijados en acetona fría y 
embebidos en parafina fue realizada por 
el método del complejo estreptovidina-
avidina-biotina-inmuno peroxidase. 
Resultados: por medio de modelos ex-
perimentales de gliomagénesis inducida 
por la ENU fue observado que es posible 
detectar células madre de tumor putati-
vo en el inicio de la oncogénesis, para 
realizar un proceso de cancerización de 
campo y observar una relación morfo-
lógica entre células positivas para MT y 
vasos sanguíneos. Conclusión: este mo-
delo experimental reproductible permite 
otros estudios involucrando el origen, 
desarrollo y factores reguladores de la 
gliomatogénesis. 
DESCRIPTORES: Glioma; 
Metalotioneína; Células madre
INTRODUCTION
Malignant glioma is the most common brain tumor. In 
contrast to the long-standing and well defined histopathol-
ogy, the underlying mechanisms of gliomagenesis are only 
just emerging. The search for the tumor stem cells that 
may originate and perpetuate the tumor growth has been 
received great attention in the literature1, but the avail-
able knowledge on this issue with regard to the gliomas is 
scant. Metallothioneins (MTs) are metal binding proteins 
that take part in the homeostasis of the metal ions and de-
toxication of metals, besides preotecting the tissues from 
the effects of free radicals, radiation and from mutagens2. 
MT expression is present in a significant portion of brain 
tumors and is higher as the malignant potential of a tumor 
increases3. MT may play a significant role in the oncogen-
esis in various types of cancer, such as the colon cancer4. 
Interestingly, in the murine colon the crypt-restricted im-
munopositivity for MT has been well established as a stem 
cell mutation marker that can be assayed in paraffin-fixed 
tissue sections4,5. The experimental model of gliomagene-
sis most commonly used, the N-ethyl N-nitrosourea (ENU) 
model, has been considered as a suitable model to study 
stage specific alterations. It was reported to appear first as 
an early neoplastic proliferation (ENP) center, which sub-
sequently progresses to tumors at different stages of de-
velopment6. Considering (a) the above discussed roles of 
MT in carcinogenesis, (b) the low level of knowledge on 
the mechanisms and origins of gliomas, and (c) the reports 
that both subpial cells and cells adjacent to the central ca-
nal of spinal cord may be target cells in the ENU experi-
mental model of carcinogenesis6, the specific objectives of 
this study were to study the MT expression in the ENU 
experimental model since early stages of oncogenesis; to 
correlate the MT expression findings with other studies, 
and to confirm the results found by Naito et al.6 with regard 
to the location of putative tumor stem cells in experimental 
gliomas, as well as to establish an experimental model to 
track glioma stem cells in early oncogenesis4.
METHODS
Thirty-six male Wistar rats provided by Faculdade de Me-
dicina de Ribeirão Preto were housed five per cage in a 
temperature-controlled room at 24 ± 1ºC, and maintained 
on a 12:12-h light-dark cycle. All animals had free ac-
cess to a commercial chow and tap water. Animals were 
weighed weekly, and weight index was calculated as the 
ratio at study completion relative to weight at study start. 
Values for mean weight index were compared between the 
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groups of treatment at study completion. The animals were 
maintained in agreement with the guidelines of the Com-
mittee on Care and Uses of Laboratory Animals from the 
National Research Council of the NIH (USA). The experi-
mental group was treated within 24 hours after birth (ne-
onate rats) with a single dose of subcutaneously injected 
ENU (40 mg/kg body weight)6. The control group animals 
were injected with the same volume of saline.
Experimental design
The animals were divided into six groups of six animals. 
The experimental groups were injected with ENU, as pre-
viously mentioned. These animals were subdivided into 
three groups according to the euthanasia time, as follows: 
the group 1 (G1) was euthanized at the age of 30 days; the 
group 2 (G2), at the age of 180 days and the group 3 (G3) 
was euthanized soon after the appearance of signs of the 
existence of nervous system tumors, at an average age of 
321 days. The control groups were euthanized at equiva-
lent ages of the experimental groups. They were named 
C1, C2 and C3, respectively.
At the respective time points, all experimental animals 
were euthanized by carbon dioxide asphyxiation and sub-
mitted to a complete necropsy. Spinal cords were fixed 
in 10% buffered formalin. All lesions and six selected 
segments of spinal cord were embedded in paraffin, sec-
tioned and stained with hematoxylin and eosin (H&E) for 
pathologic evaluation of tumors. The paraffin-mounted 
serial sections of the rat’s spinal cord were used for MT 
immunohistochemistry staining. Immunohistochemical 
detection of MT protein in cold acetone-fixed paraffin em-
bedded spine cord sections was performed by the strepta-
vidin-avidin-biotin-immuno peroxidase complex method, 
as previously described5,7. Two investigators (SB Garcia 
and Vinicius) independently evaluated the immunohisto-
chemistry. Both observers were blind to the identification 
of groups. MT immunostaining was considered positive 
when the nuclei and cytoplasm of the nervous tissue cells 
were prominently stained (purplish brown/reddish brown). 
The pattern of MT staining was also characterized as cyto-
plasmic only, nuclear only, and both cytoplasmic and nu-
clear. MT positive cells were quantified per microscopic 
field. A total of 10 high power (40x) fields were randomly 
chosen. The number of positive vessels was evaluated per 
mm of the spinal cord surface length. 
The tissue sections of spinal cord stained with immuno-
histochemistry were divided into three areas: A1, subpial 
region (a 50µm thick margin from the pia matter); A2, the 
nervous tissue parenchyma, including white and gray mat-
ter; and A3, area surrounding the central canal of the spinal 
cord. Five slides representing each animal were evaluated 
for each study. Only spinal cord tissue with normal ap-
pearance was considered for the study of the Groups C1, 
G2, C3, G1 and G2. For the A2 first study evaluation, five 
microscopic fields at medium-power (40x) were randomly 
taken from different sites on each immunostained tissue 
section and up to two blocks used from the same animal 
taken from different regions of the spinal cord.
Data were statistically analyzed by the ANOVA test. 
Differences were considered to be significant when p≤0.01.
RESULTS
Apart from the G3, all animals remained in good health 
and none showed clinical signs of nutritional deficiency 
during the experimental period. At the end of the experi-
ment, the average weight of all animals did not differ be-
tween the groups at the same time point. In G3, clinical 
signs of spinal cord involvement developed over a period 
of days to weeks. Most commonly, a unilateral posterior 
paresis was followed by bilateral paralysis. In these ani-
mals, tumors were located most frequently in the lower 
thoracic and lumbar regions of the spinal cord. Hema-
toxylin and eosin staining of paraffin-embedded tumors 
have shown the presence of nodular lesions mainly in the 
white matter of the spinal cord (not shown). At a higher 
magnification, the nodules consisted of well differentiat-
ed oligodendrogliomas. The neuroepithelial origin of the 
tumors was confirmed by the GFAP immunostaining, that 
was positive in all lesions, and leucocyte common anti-
gen (LCA) negative (data not shown). All tumors showed 
a biphasic pattern consisting of round and weakly MT 
stained cells in small number in the tumor core, and a 
number of spindle highly stained MT-positive cells sur-
rounding the tumors and their desmoplastic stroma (Fig-
ure 1A). We named these cells Metallothionein-Over-
Expressing-Cells (MTOEC). The METOC were lined 
with the tumor boundaries at their surface, contacting the 
apparently normal surrounding tissue (Figure 1B). In the 
MTEOC, the immunohistochemical localization of MT 
was demonstrated in both the cytoplasm and the nuclei of 
the apparently normal nervous tissue cells and in the tu-
mors (Figure 1B), whereas in the control animals the MT 
staining was present in a small number of round cells, 
with a considerably weaker attaining and localized only 
in the cytoplasm (Figure 1C). The control animals did not 
show the presence of MTOEC in any of the three evalu-
ated regions of the spinal cord.
In the ENU-treated groups G1 and G2, MTEOC were 
also found. These cells were very similar to those found in 
the tumors boundaries (G3). In the G1, the MTEOC were 
found only in the subpial region, with no strong MT stain-
ing in the other assessed spinal cord regions. The MTEOC 
were also observed in the subpial region of the spine 
cord of the G2 animals (Figure 1D), and the frequency 
of MTOEC was approximately twice higher than that of 
G1 animals (23.9±1.9 and 12.3±1.2 cells per histological 
section, respectively; p<0.01, ANOVA test). Furthermore, 
in G2 animals, scattered islands with groups of MTEOC 
were seen, as well as blood vessels acquiring MT posi-
tivity at their peripheral zone facing the endothelium, and 
some positive cells were found not only in the subpial re-
gion (Figure 1D).
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DISCUSSION
Glioma is the most common primary tumor of the brain, 
but very little is known about the processes through 
which it develops. It is useful and necessary to have 
animal models for the existing central nervous system 
tumors that allow studies to be carried out in different 
stages of growth, especially in the early stages, that are 
difficult to be observed in clinical practice8. To the best 
of our knowledge, MT expression had not been stud-
ied in experimental models of gliomas yet. This paper 
showed that the administration of a mutagen to one-day-
old rat leads to the formation of scattered subpial MT 
positive cells after 30 days, and that the frequency of 
these cells is (a) strongly correlated with the increased 
appearing of early neoplastic proliferation (ENP) cent-
ers and new blood vessels, (b) is augmented at higher 
levels in long-term observation, 180 days after the car-
cinogen administration, (c) is related to a high staining 
intensity in both nucleus and cytoplasm, and (d) is very 
similar to the pattern of immunostaining that was ob-
served in the nervous tissue surrounding the gliomas, 
which were originated at an average of 321 days after 
the ENU administration.
In the normal nervous tissue, the MT expression has 
generally been associated with heavy metal detoxifica-
tion, intracellular trace elements storage and scavenging 
of free radicals. An increased expression of MT is nor-
mally associated with exposure to stress and inflamma-
tion. In these circumstances, expression in the tissues is 
diffuse and short-lived, returning to baseline levels ap-
proximately 20 hours after the exposure of an inflamma-
tory stimulus9. The ENU induced over expression of MT 
Figure 1
Spinal cord of rat immunostained for metallothioneins (MT). (A) Higher magnification of boxed area in (B). Note the highly MT 
stained cell (MTEOC) situated in niches that are only located in the peri-vascular area; (B) Presence of metallothionein-positive 
cells in a small oligodendrioma 321 days after ENU treatment. Note the presence of highly positively stained cells (MTEOC) in 
the neighboring area of the tumor (arrows); (C) Weak immunoreactivity for metallothionein in isolated cells of the spinal cord of 
a normal control animal (arrows); (D) A large number of MT-positive cells (black arrows) are found at the subpial region of the 
spinal cord 180 days after ENU treatment. Most of the MT-positive cells are near vessels. Some MTEOC are seen deeper in the 
spinal cord parenchyma, far from the subpial region (white arrow).
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(MTOEC) in our findings is clearly different because (a) 
it is highly and specifically restricted to the subpial area 
of the spinal cord, at the same location of putative tar-
get cell in the ENU carcinogenesis model6 and (b) the 
staining pattern of the affected cells is far more intense, 
affecting both cytoplasm and nucleus, than the eventual 
findings in positive cells of control animals or in the 
inflammatory stimulated MT expression, as reported in 
the literature10.
The MTOEC herein described are similar to the pre-
viously described MTOEC that spread in the colon and 
liver of mouse treated with a single dose of carcino-
gen5,11. In both organs, the MTOEC are considered to 
be useful positive markers for stem cells in preneoplas-
tic lesions12, though the mechanisms and reasons why 
MT is overexpressed in these cells remain to be eluci-
dated. It has been hypothesized that mutation-induced 
MT overexpression may interfere with the function of 
zinc finger DNA binding transcription factors, which 
have been implicated in transcriptional control of vari-
ous genes, including p53, involved in cell proliferation 
and apoptosis13. These MT-mediated effects on gene 
transcription are thought to confer a selective growth 
or survival advantage (or both) on the mutated cells13. 
The vast majority of the MTOEC in our study expressed 
MT in both cytoplasm and nucleus of ENU-treated ani-
mals, what strongly suggests that these MTOEC are mu-
tant cells, as reported in other studies5. Regardless the 
causes and consequences of this over-expression of MT, 
if one assumes that MTEOC are mutant stem cells, it 
may provide a new way to track mutated stem cells. It is 
thought that stem cells live in protected pockets of the 
body called niches, where they divide infrequently to 
avoid accumulating damaging mutations. Upon injury 
or in response to normal stimuli, stem cells are mobi-
lized to divide14. Parallel to the role that normal stem 
cells play in organogenesis, stem cells are thought to be 
crucial for tumorigenesis. 
The existence of a number of mutated MTOEC that 
spread in the nervous tissue of carcinogen-treated ani-
mals fits well in the “field cancerization theory”. We 
had previously discussed that, according to this theo-
ry, a stem cell acquires genetic alterations and forms 
a “patch”, a clonal unit of altered daughter cells15. The 
proliferation of these patch cells forms expanding fields 
which gradually displace the normal tissue and by clon-
al divergence ultimately leads to the development of 
one or more tumors within a contiguous field of pre-
neoplastic cells. The field cancerization theory implies 
that the mutated genotype and molecular changes oc-
cur before the appearance of histopathological evidence 
of malignant cells15. An important clinical implication 
is that fields often remain after primary tumor surgery 
and may lead to new cancers, designated presently by 
clinicians as “a second primary tumor” or “local recur-
rence”, depending on the exact site and time interval16. 
The main practical problem is how to identify, mark 
and track the cancerization fields. Based on our findings 
and on the literature considerations, we suggest that MT 
staining is a candidate to such task.
Neural stem cells arise from a region called radial 
glia (RG) within the central nervous system and the RG 
cells produce neurons in addition to glia during central 
nervous system development in all vertebrates and are 
also involved in reparative process17. Comparing the 
gene expression profiles of ependymomas to those of 
cells in the normal developing nervous system, it was 
possible to pinpoint the RG cells as candidate stem cells 
of this brain tumor14. Our data adds great support to this 
hypothesis, since the main location of the ENU-induced 
MTOEC herein described present striking similarity to 
the radial glia cells; however, this relationship needs 
further detailed investigation.
Furthermore, our results clearly show the exist-
ence of a close morphological relationship between 
MTOEC and blood vessels. But what is the functional 
relationship between them? It is known that MT is in-
volved in the regulation of the functions of endothelial 
cells, as well as in their protection against cytotoxic 
agents18. MT knock-out (MT-KO) mice presented dra-
matically decreased IL-6-induced angiogenesis caused 
by cortical freeze injury, suggesting that the MT have 
major regulatory functions in the angiogenesis proc-
ess10.  Interestingly, recent data suggest that stem cells 
of glioblastoma are situated in close proximity to en-
dothelial cells and seem to be dependent on cues from 
aberrant vascular niches that mimic the normal neural 
stem cell niche, facilitating communication between 
these cell types, what may influence the stem cell reg-
ulation19,20. Supported by our findings, we suggest that 
MT may play a role in such relationship, which war-
rants further investigation. A recent review article on 
gliomagenesis addresses the following key question: 
are cancer stem cell niches the primary drivers of tu-
mor development, or are they recruited by pre-formed 
cancer stem cells?19 From our findings, it is possible to 
suggest that the second option is more likely to occur, 
since we have observed a higher number of isolated 
MTOECs at 30 days after ENU injection than after 180 
days. At this last time point, most of the MTOECs are 
located in close relationship to endothelial cells, sug-
gesting that MTOEC may induce angiogenesis around 
then.
Finally, we and other authors have shown that the 
amount of MT overexpressing cells correlates well with 
factors that are known to influence colon carcinogenesis, 
such as the non-steroidal anti-inflammatory drugs and 
diet4,7. In case this occurs in the glia, the MT staining may 
provide a simple and reliable method to design short-term 
studies to verify factors that could influence gliomagen-
esis, by evaluating the number of MTOEC formation and 
proliferation. It must be pointed out that putative risk 
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factor for gliomas are currently poorly known, at least 
partially because of a lack of feasible and reliable experi-
mental models to test then, as there are largely available 
methods to study oncogenesis modulator factors in other 
organs. In conclusion, we developed a reproducible model 
for marking and quantifying putative mutant stem cells re-
lated to gliomagenesis, allowing further studies on their 
origins, development and regulating factors.
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